ID   240E-W
AC   CVCL_Z068
DR   Wikidata; Q54583426
RX   Patent=US10377814;
RX   PubMed=21633632;
CC   Group: Hybridoma fusion partner cell line.
CC   Selected for resistance to: ChEBI; CHEBI_63486; 8-azaguanine.
DI   NCIt; C133738; Rabbit plasmacytoma
OX   NCBI_TaxID=9986; ! Oryctolagus cuniculus (Rabbit)
HI   CVCL_J972 ! 240E1-1-2
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 9
CH   CVCL_Z069 ! 240E-W2
CH   CVCL_A0GZ ! 5210-87-13
CH   CVCL_C3X6 ! mAbHpu24
CH   CVCL_C3X7 ! mAbHpu91
CH   CVCL_C3X8 ! mAbHpu98
//
RX   PubMed=21633632; PMCID=PMC3102571;
RA   Feng, Li-Feng
RA   Wang, Xian
RA   Jin, Hong-Chuan
RT   "Rabbit monoclonal antibody: potential application in cancer
RT   therapy.";
RL   Am. J. Transl. Res. 3:269-274(2011).
//
RX   Patent=US10377814;
RA   Pytela, Robert
RA   Zhu, Wei-Min
RA   Ke, Yao-Huang
RA   Qian, Qi
RA   Au, Harry C.
RT   "Fusion partner for production of monoclonal rabbit antibodies.";
RL   Patent number US10377814, 13-Aug-2019.
//